Why RNA is the future of diagnostics
Weve come a long way from the early days of using medicinal leeches and mercury treatments as therapeutics. As described in the book Soonish, the path to precision medicine has been a long one, often lacking scientific rigour and sometimes, common sense.
Thankfully, on the diagnostics front, weve advanced further than posthumous autopsies and microscopic pathology developed in the nineteenth century. Today, molecular diagnostics have become commonplace in medicine. Looking into the future, how will the innovations of today shape the face of medicine ten or twenty years from now? We may see the biggest change occur in genomics, with a battle of the bases determining which biomolecule will reign supreme for biomarker discovery.
In one corner is DNA, or deoxyribonucleic acid, in the other corner is RNA, or ribonucleic acid. These two contenders are known for their respective and important roles within the central dogma of biology. And, while both are composed primarily of a sugar and base combination, major differences exist. First, the base pairs differ slightly since DNA uses the bases adenine, thymine, cytosine and guanine while RNA uses adenine, uracil, cytosine and guanine. Second, DNA most often exists as a double-stranded molecule, while RNA is usually found in its single-stranded form. RNAs bonus hydroxyl group results in decreased chemical stability relative to DNA. This, coupled with the pervading presence of RNases, results in a much shorter lifetime for RNA, and is a third defining difference between these two biomolecules.
Finally, while most organisms have only two copies of DNA per cell, even low abundance RNA transcripts often have hundreds of copies present per cell (or organism).
So, lets start off with a warm-up match: infectious diseases. RNAs ubiquitous nature affords an advantage here. Diagnostics which are developed to detect RNA species for infectious organisms could require less patient material or detect the infection earlier due to a stronger signal compared to their DNA counterparts. Further, as described by John Brunstein, if a transcript or set of transcripts is selected correctly, an RNA diagnostic could also provide a measurement of viability of the infectious agent. Looks like RNA has taken an early lead.
One more bout to get warmed up: autoimmune disease. Since the completion of the Human Genome Project and with the introduction of high-throughput sequencing, weve been able to collect massive amounts of DNA data from both healthy and diseased patients. These data sets have enabled us to determine genetic changes implicated in many diseases, including autoimmune diseases like rheumatoid arthritis (RA) and multiple sclerosis (MS). However, one challenge that remains is that DNA only reports on the risk or potential for developing one of these diseases. RNA, however, gets us one step closer to the downstream biology, and can greatly help disease diagnosis. By analysing RNA signals, its been reported that earlier, more accurate diagnosis can be achieved. This warm-up round goes to RNA, as well.
And now, for a championship match of great significance: Cancer.
This disease, or rather an assemblage of diseases, still represents the second most prevalent cause of death in the world. Despite immense improvements in understanding cancer biology and using this to develop new and impactful treatments, including targeted therapies, immunotherapies, cell therapies and cancer vaccines, we still see only a small percentage of patients benefiting with robust responses. Cancer, with its combination of hereditary, environmental and sometimes random origins, has required diagnostic approaches covering many fronts.
Round 1: genetic mutations For hereditary cancers, there are a number of mutations that have been determined to play a major role in the likelihood of developing the disease or the path of disease progression. In breast cancer, for example, these include BRCA1 and BRCA2, along with the less commonly discussed PTEN and p53 mutations.
However, for many patients, a genetic analysis delivers a number of mutations which are listed as Variants of Unknown Significance. These mutations are known to be different from a normal genome, but there is not sufficient clinical evidence to use the information to make medical decisions. However, when RNA data is layered on top of this genetic data, additional context may be used to determine whether these variants should be classified as pathogenic or benign. As described above, while were still looking at risk factors in this case, the additional clarity provided by RNA can make a big impact in determining whether a patient receives preventative surgery or more rigorous surveillance. Round 1 goes to RNA.
Round 2: gene fusions Understanding the mechanisms of cancer that impact progression and pathogenesis are imperative to improving treatment plans. Further, specific molecular events have also informed therapy selection, more commonly known as targeted therapies. One excellent example is in non-small cell lung cancer, where the EML4-ALK gene fusion, arising from chromosomal rearrangement, has become both a diagnostic marker and a target for ALK inhibitor therapies. In the diagnostic arena, fluorescence in situ hybridisation (FISH) of the two DNA sequences has been used to detect the presence of this gene fusion. However, there is significant genomic heterogeneity in these ALK rearrangements undetectable by FISH, which has been shown to be related to differences in kinase inhibitor treatment response rates. Use of RNA sequencing technologies, which look not only for expression of these fusions but also enable discovery and quantification of novel fusions, has enabled the field to move beyond the limited information provided by DNA diagnostics. RNA wins another point.
Round 3: immune response Undeniably, the most promising path to understanding and treating cancer is immuno-oncology. This approach, which harnesses the bodys immune system to fight the disease, has garnered much attention, resulting in the 2018 Nobel Prize in Medicine. While these therapies show enhanced and lasting responses, a number of challenges remain. DNA technologies, including tumour mutational burden (TMB), showed promise in predicting response to immune checkpoint inhibitors; however, the results in the clinic were disappointing. Understanding the dynamic immune composition at the site of the solid tumour is imperative, and new approaches using RNA models to achieve that are showing the promise that RNA will have in this space. It may be too early to call this round for RNA, but it is beginning to make a case.
Concluding thoughts
As it turns out, the battle of the bases was not really a fair fight. The advances in high-throughput sequencing and analysis that have bolstered our databases of DNA information have in parallel provided us with a plethora of RNA data to mine and interpret. Further contributing to this are enhanced tools for analysing chemically and enzymatically degraded RNA, removing a roadblock that previously existed. Now, instead of seeing RNAs lability as a weakness, its dynamic nature is now considered a massive advantage. We can measure the impact of therapy and disease progression in the bodys ever-changing RNA. Today, the field is focused on building and validating new tools using RNA to aid physicians in understanding what causes disease, when disease will manifest itself, how we can predict which therapies will benefit individual patients and when disease will recur or progress. From infectious diseases to oncology, and likely in areas we have not yet discovered, RNA diagnostics will certainly be a key chapter in the tome entitled precision medicine that so many of us in the industry are currently writing. And, if successful, may help us knockout some of these malevolent diseases.
Jarret Glasscock is a geneticist, computational biologist, and founder and chief executive of Cofactor Genomics
Continue reading here:
Biomarkers and a battle of the bases - PharmaTimes
- IOM not webcast today. Why Not? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- National Academies skeptical at Best. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Some Confusion Exists [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Why DTC Genomics IS Medicine. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- First Mari, Now Linda. Who's next? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Is it true? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Re-Reviewing the National Academies [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- The problem with nonclinicians....... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Crazy Night of Emails to Government [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Adrienne Carlson's Personalized Medicine. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Tell Me, How do you feel now? Sherpa's RX [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- This Just In. 23andMe to go to GPs. I love my readers!! [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Sorry so long away [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- 2D6 Rears its ugly head..... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Ok, Fine, Back to Plavix [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Kaiser a protoype for Collins' Aim [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- A few months late to the party.... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Stated Another Way....... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Excuse Me? Harvard and Navigenics? WTF? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Follow up to Yesterday's WTF? Harvard, Navi? and Pfizer??? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Did you get your kit? Thanks Dr. Rob from MedCo [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Gluco...Wha? Parkinson's Disease and Glucocerebrosidase mutations. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Away and now back, What did I miss???? 23andme layoffs? Selling Genomes for cheap up next! [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Change IS Needed. I agree with William, sometimes. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Good Enough Science? Apparently so at 23andme [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Long QT Syndrome, location matters [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Congratulations Generation Health. Nice pick up! [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- An argument 23andSerge can't win...23andme but not medicine [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Stop. Breathe. Repeat. An analysis of the direction of DTC Genomics Field. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Hey DTC genomics, Stay Private, Stay Alive, Go Public and Die [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- You can't have it both way. Either scared your genome is sold off or not. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- 15 Days Away Gives Time for Perspective. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- What about the SACGHS registry? Another missed opportunity? [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- AJHG is in and my Favorite Muin is in it! But He Is NOT the Father! [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Navigenics for 23andMe prices? [Last Updated On: December 18th, 2009] [Originally Added On: December 18th, 2009]
- Lp(a) Maybe there's something there that wasn't there before? [Last Updated On: December 24th, 2009] [Originally Added On: December 24th, 2009]
- Another Year, Another Bankruptcy [Last Updated On: December 31st, 2009] [Originally Added On: December 31st, 2009]
- 5 Technologies going bye bye in this decade? [Last Updated On: January 6th, 2010] [Originally Added On: January 6th, 2010]
- Hackers, HITECH and HIPAA in DTC Genomics, Oh My! [Last Updated On: January 7th, 2010] [Originally Added On: January 7th, 2010]
- Personal Genomics Flop.....big Belly Flop! [Last Updated On: January 8th, 2010] [Originally Added On: January 8th, 2010]
- Gotta Love It. Even the daycare....... [Last Updated On: January 11th, 2010] [Originally Added On: January 11th, 2010]
- Congratulations Navigenics. You ARE a clinical lab! Uh-Oh... [Last Updated On: January 12th, 2010] [Originally Added On: January 12th, 2010]
- CETP, Jewish Centenarians and Alzheimers [Last Updated On: January 14th, 2010] [Originally Added On: January 14th, 2010]
- Enter the "Not" DTC Genomics Rep [Last Updated On: January 17th, 2010] [Originally Added On: January 17th, 2010]
- Why Dr. Vanier's Navigenics appointment is good for PM [Last Updated On: January 22nd, 2010] [Originally Added On: January 22nd, 2010]
- Holy Crap! MedCo Follows in CVS footsteps [Last Updated On: February 3rd, 2010] [Originally Added On: February 3rd, 2010]
- FDA, Warfarin, still not as sexy to me. [Last Updated On: February 5th, 2010] [Originally Added On: February 5th, 2010]
- Hype, Hype, Hype from a single study. [Last Updated On: February 11th, 2010] [Originally Added On: February 11th, 2010]
- I love my readers, even Renata M! [Last Updated On: February 17th, 2010] [Originally Added On: February 17th, 2010]
- How can insurers use DTC genomics to profile? [Last Updated On: February 17th, 2010] [Originally Added On: February 17th, 2010]
- 9p21.....ahem. Paynter et.al. Smackdown. Again. [Last Updated On: February 18th, 2010] [Originally Added On: February 18th, 2010]
- Hey! It's Pete Hulick! Are you Going to GET? [Last Updated On: February 19th, 2010] [Originally Added On: February 19th, 2010]
- I was wrong......AHEM [Last Updated On: February 28th, 2010] [Originally Added On: February 28th, 2010]
- G2C2, finally a tool for genomic education! [Last Updated On: March 2nd, 2010] [Originally Added On: March 2nd, 2010]
- Just 4 million? What 23andMe is worth. [Last Updated On: March 5th, 2010] [Originally Added On: March 5th, 2010]
- What a difference a year makes [Last Updated On: March 9th, 2010] [Originally Added On: March 9th, 2010]
- ........DTC Genomic Medicine? [Last Updated On: March 12th, 2010] [Originally Added On: March 12th, 2010]
- The FDA, 2c19 and the ACC [Last Updated On: March 13th, 2010] [Originally Added On: March 13th, 2010]
- The problem with Comparative Whole Genomics...... [Last Updated On: March 13th, 2010] [Originally Added On: March 13th, 2010]
- BRCA testing by 23andME is the same as Myriad Genetics. [Last Updated On: March 15th, 2010] [Originally Added On: March 15th, 2010]
- The Argument Against DTC Genomics Marketing and such [Last Updated On: March 16th, 2010] [Originally Added On: March 16th, 2010]
- A moment of Clarity. Some DTCG is not bad. [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- SNPs for breast cancer risk? It Depends. [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- How can MDVIP use Navigenics Test for Medicine? [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- Why did P&G invest in Navigenics? [Last Updated On: March 23rd, 2010] [Originally Added On: March 23rd, 2010]
- PGx in DTCG? Doesn't stand up to Useful testing. [Last Updated On: March 25th, 2010] [Originally Added On: March 25th, 2010]
- End of Gene Patents? [Last Updated On: March 29th, 2010] [Originally Added On: March 29th, 2010]
- Sherpa Accepting Chief Medical Officership [Last Updated On: April 3rd, 2010] [Originally Added On: April 3rd, 2010]
- The Rumors of My Death........ [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- Happy DNA Day! [Last Updated On: April 25th, 2010] [Originally Added On: April 25th, 2010]
- 99 USD, DNA day and patient letters [Last Updated On: April 25th, 2010] [Originally Added On: April 25th, 2010]
- 2C19, Navigenics and Clinical Reality. [Last Updated On: May 1st, 2010] [Originally Added On: May 1st, 2010]
- Coriell Personalized Medicine Collaborative rising [Last Updated On: May 7th, 2010] [Originally Added On: May 7th, 2010]
- Personal Genomes in Clinical Care. Quake paper is a waste! [Last Updated On: May 11th, 2010] [Originally Added On: May 11th, 2010]
- Personal Genomes in Clinical Care. Quake paper Falls Short! [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- Last post edited by Drew [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- GateKeeper? FCUK U! [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- GateKeeper? F! U! [Last Updated On: May 15th, 2010] [Originally Added On: May 15th, 2010]
- Potential of genomic medicine, LOST [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- How Bad Can a House Investigation be for DTC Genomics? [Last Updated On: May 20th, 2010] [Originally Added On: May 20th, 2010]